Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Excellent scientific and financial analysis SOG. We are back in the race again despite the mugging along the way. Its been a bare knukle ride and we have survived it. I think that the scientific expertise shared on this board by you and some others has helped greatly to give the confidence needed to stay invested in this company.
Thank you Rebster,
That's exactly what I was asking for.
All the best,
CrestEx
Good evening fearg,
Similar opinions as myself, definate downward pressure by RF to to put financial destruction on Sareum. From the RNS of today the rerate has begun.
RF can sell what they like. Hence gradual grind over 6 months,from Aug to Feb (105p to 60p ) and then from Feb to March dropped 60p to 10p.
Another raise and shares may have been manipulated down to less than a penny. RF come along kindly help with more peanut finance and acquire Sareum. Sold in the hundreds of millions later!
Share price was 105p prior to RF involvement.
Circa 70 million shares at that time, now around 105 so approx 50% dilution.
So realistically we are looking at 70p per share to bring the SP or to be more precise the Market Cap of 70 million.
Now 1801 has advanced since, as we now await safety data results that we expect to enable us to traverse into a company that has a phase 2 asset.
In addition we await news of the licensee that has taken on 737 a checkpoint 1 kinase inhibitor.
Checkpoint kinase inhibitors are effective at what they are designed to do, but to satisfy the demands of regulating authorities such as the NDA they need to be used in combination therapy satisfactorily to gain clinical use authorisations.
With regards to 1801 that will also have a knock on effect to 1802.
I would suggest that on satisfactory 1801 news we can expect a minimum 50% to 100% rise. On commencement of phase 2a trial (that may require raising of funds to bring the Mcap to around 150 to 175 million.
News on 737 maybe 5 to 7.5 million as a rough guide.
155 to 180 million market cap
Approx 150p to 180p per share.
On licence will depend on phase 2 data.
End of phase 2 as l have put before an upfront payment of between 200 and 400 million and with good Indications outside of psoriasis maybe up to 800 million.
No Jaki inhibitors irrelevant of selectivity have ever been authorised for clinical use without the dreaded black box warnings.
Allosteric TYK2 Deucravacitinib)has proven so far excellent with regards to safety albeit the efficacy on Psoriasis is adequate, it is believed by using the dual inhibition approach of Tyk2 and Jak1 that this would yield superior efficacy over Tyk2 alone. 1801 is Tyk 2 Jak1 an oral formulation that has the added underestimated benefit of being administered in a capsule formulation.
The safety profile of SDC-1801 if comparable to Deucravacitinib would make us available for clinical use without the dreaded black box warnings and a greater efficacy in certain Indications.
Let's face it Deucravacitinib flunked badly in UC.
This all new allosteric Tyk2 inhibitor that regulates the active domain via the pseudo domain?
How much would 1801 be worth with a safety profile comparable with Deucracitinib but better efficacy?
Mind blowing!
Regards
I'm intrigued by Sareum's phasing in the SRA737 section: "Identification of partner"
Do they expect it to come to light sooner rather than later? Fingers crossed we get plans of a phase 2 or 3 combo trial with concrete timelines for milestone payments - i.e. securing funding for SDC1801 phase 2 in the process
So what's stopping it going to £1 + considering it was £1.47 a year ago , look where Sar is now :)
More expert analysis
Nothing in the way now :)
Thank you for the link. Very useful.
In a nutshell..
https://sareum.com/wp-content/uploads/2024/03/Sareum-Company-March-2024-for-website.pdf
Now digest, Sareum survived the fiasco!
Good riddance to RF, now let the fun begin
GLALTH's ;)
August- see RNS- death spiral begins with SP around 100p
March- placing at 10p
April-death spiral finishes and recovery begins.
Simples.
Crest
We took a very poor finance deal with Riverfort which along side some questionable motives from Peel? And spivs battered the SP. We have now cleared the finance deal that was hurting us and are cash in the back and waiting results which should propel the sp back towards £1:50 at least IMO
Have been at a funeral most of day so catching up on price movements and banter. Won’t sell any till this gets back to where it should be at the moment which is £1.
Indeed Joey...it's as though the RNSes are invisible at top of page...🙄😁
Zzzzzzzzzzzzzzzz....never ending array of numpties over the last 2 weeks
Hi All,
Sorry to be asking this but theres too much info to wade through here and the RNSs don't really make any sense to me.
I've had quite alot going on over the last couple of years and haven't really looked at this but noticed today that the SP has moved and the board has lit up.
Can somebody please briefly explain what I've missed and what were expecting :)
TIA
Cobalt
Yes so I suggest metaphorically 😂😂
HE1 was a laugh. I bought back into it at 0.060 and watch it hit 3p when I bailed.
Only wished I had more funds to buy in at that low SP. Two days of 100% SP increase and the a following day of cooling down. It will go again when it gets closer to Q3.
As you say, SAR feels the same I'm hoping that with RF gone, investors will want to load up whilst it's still under 50p.
Although I didn't catch this at 10p, I do think it has the legs to run up to 75p and over £1 on new news.
Do you know what a Warthog looks like?🤣🤣
This has moved like HE1
A Huge placing filled well below the go to market price. Of which a decent whack of that subscription was from institutions….
If there is news tomorrow/this week we might be have a real monster on the risers board. HE1 15 bagged in the space of two weeks. Of which it had 3 days on the bounce where 90-130% daily gains. Feels a little similar.
Might not happen of course. But does feel the same with the buzz that’s coming.
Also with HE1, I sold after it did 300%. I then had NT as it flew through multiple pennies. If you are out this now, be prepared you very well might have to wait a while before you can rebuy
#talesfromthetradingfloor
lol
Best
BigE
Warty
He wasn’t being nasty.. you two should kiss and make up 🙄
Aha! I see a filtered message! Must be CBlue having one of his periodic outbursts of vitreol!
I would expect that this is the beginning of the rerate rather than the beginning of the end with plenty more news to come. On thing is certain and that there is never certainty, but the omens are positive.
We have been through the mill on this and I believe the trap door was being prepared. I think the forces of darkness thought that with the sp on the floor and funding withdrawn, probably as planned, that SAR would fail. Perhaps a share price of aprox 2p was being prepared for the investors on a take it or leave it basis, after which the company would go private and be set up, after the completion of P1a, to be flogged at a massive markup to a pharma.
We deserve to be informed by the BOD who it was who suggested RF and who knew their form. It must have been well known as Puma was telling us all about how it would pan out. Without shareholder participation it is unclear whether we could have survived.
We need to know for the simple reason that how can we be sure thatsuch a scenario won't be hoisted on us again in the future.
Issues like consolidation were imposed on us with no regard for the views of the owners of this company, the shareholders.
I believe that the BOD, while negligent, they did shape up when heel come to shove in organising the recent funding arrangement.
I'm about the same warthog I tend not to look to much when it's rising , I certainly can't call this one I thought RF was priced in.....
Well done Carrots - that's a tidy profit :-)
Enjoy.
My dear boy, a profit is not a profit until the cash is in the bank. Well done carrots.